VANCOUVER, BRITISH COLUMBIA -- (Marketwire) -- 01/11/13 -- Pyng Medical Corp. (TSX VENTURE:PYT) today announced financial and operating results for the fiscal year that ended September 30, 2012. All amounts are in Canadian dollars unless stated otherwise.

The Company reported total sales of $4,540,399 for fiscal year 2012 (October 1, 2011 - September 30, 2012), down 25% from the $6,050,421 reported for fiscal year 2011. This revenue decline is primarily attributed to significant cutbacks in purchases from the U.S.A. military during this period, assumed to be related to ongoing Federal budget concerns as well as changing military conditions in Afghanistan and elsewhere. International (outside United States) revenues grew 11% during fiscal year 2012. Gross margin of $2,780,369 was reported for fiscal year 2012, down to 61% of revenue from 64% one year ago. This small reduction was primarily attributed to higher raw material cost during the year. Total operating expenses decreased 24% to $2,872,780 from $3,790,992 a year ago, primarily related to improved efficiencies in parallel to cost-cutting actions the Company has taken in the midst of declining revenues.

The Company also reported a net loss of $1,049,452 for fiscal year 2012, which included a net loss of $1,229,440 recorded related to product CRIC. Primarily due to the impact of this loss, loss per share expanded to $0. 07 for fiscal year 2012 compared to net loss of $0.03 per share for fiscal year 2011. Earnings before interest, depreciation, amortization and taxes ("EBITDA") from continuing operations decreased to $488,637 during the year (11% of revenues) compared with EBITDA of $555,962, (9% of revenues) for fiscal year 2011.

For the fourth quarter ended September 30, 2012, the Company recorded sales of $957,032, slightly lower than $995,611 reported for the comparative quarter of fiscal year 2011. A net loss of $1,229,440 was recorded related to product CRIC during this quarter, which was comprised of impairment loss of $1,856,315 on intangible assets offset by the other long-term liabilities write-off of $626,875. As a result, total expenses increased by 28% to $1,917,652 from $1,497,055 reported a year ago and the net loss rose to $1,042,510 from $860,400 for the comparative quarter of last year.

As at September 30, 2012, the Company had a working capital deficiency of $196,463, which represents a decrease of $310,173, compared to working capital surplus of $113,710 reported on September 30, 2011. The decline in working capital was primarily caused by a decrease in revenues combined with redevelopment costs related to the FASTx product that was recalled in November 2010 (estimated at US$2,000,000 in total redevelopment costs going back to November 2010).

The Company is currently pursuing additional debt and/or equity financing to fund working capital needs. Management hopes to secure the necessary financing through the combination of new credit facilities and issuance of new equity or convertible debt instruments. There can be no assurance that these initiatives will be successful.

Full audited financial results for fiscal year ended September 30, 2012 are available on SEDAR at www.sedar.com.

About Pyng Medical Corp.

Pyng Medical Corp. commercializes award-winning trauma and resuscitation products for front-line critical care personnel. Pyng's expanded product portfolio includes a variety of innovative, lifesaving tools. With growing markets in North America, Europe and Asia, Pyng offers user-preferred medical devices for use by hospital staff, emergency medical services and military forces worldwide.

Safe Harbour Statement; Forward-Looking Statements: This release may contain forward-looking statements based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. Some of the forward-looking statements may be identified by words like "expects", "anticipates", "plans", "intends", "projects", "indicates", and similar expressions. These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions. Many factors, including those discussed more fully elsewhere in this release and in documents which may be filed with the British Columbia Securities Commission, the Alberta Securities Commission, the Ontario Securities Commission, the TSX Venture Exchange, as well as other USA Commissions, could cause results to differ materially from those stated. These factors include, but are not limited to changes in the laws, regulations, policies and economic conditions, including inflation, interest and foreign currency exchange rates, of countries in which the Company does business; competitive pressures; successful integration of structural changes, including restructuring plans, acquisitions, divestitures and alliances; cost of raw material, research and development of new products, including regulatory approval and market acceptance; and seasonality of sales in some products.

Neither the TSX Venture Exchange nor its Regulatory Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.